SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Acumen Pharmaceuticals, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Tuesday, 3/26/24, at 9:16am ET   ·   For:  12/31/23   ·   Accession #:  1576885-24-47   ·   File #:  1-40551

Previous ‘10-K’:  ‘10-K’ on 3/27/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/26/24  Acumen Pharmaceuticals, Inc.      10-K       12/31/23   83:61M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.62M 
 2: EX-10.13    Material Contract                                   HTML    192K 
 3: EX-10.14    Material Contract                                   HTML    161K 
 4: EX-10.15    Material Contract                                   HTML    241K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     26K 
10: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     37K 
                Awarded Compensation                                             
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
16: R1          Cover                                               HTML     92K 
17: R2          Audit Information                                   HTML     30K 
18: R3          Balance Sheets                                      HTML    123K 
19: R4          Balance Sheets (Parenthetical)                      HTML     45K 
20: R5          Statements of Operations and Comprehensive Loss     HTML     88K 
21: R6          Statements of Changes in Stockholders? Equity       HTML     77K 
22: R7          Statements of Changes in Stockholders? Equity       HTML     26K 
                (Parenthetical)                                                  
23: R8          Statements of Cash Flows                            HTML    119K 
24: R9          Description of Organization and Business            HTML     34K 
                Operations                                                       
25: R10         Basis of Presentation, Summary of Significant       HTML     75K 
                Accounting Policies and Recent Accounting                        
                Pronouncements                                                   
26: R11         Marketable Securities                               HTML     99K 
27: R12         Fair Value Measurements                             HTML     75K 
28: R13         Supplemental Financial Information                  HTML     43K 
29: R14         Leases                                              HTML     60K 
30: R15         Debt                                                HTML     44K 
31: R16         Stockholders? Equity                                HTML     38K 
32: R17         Stock-Based Compensation                            HTML     63K 
33: R18         Income Taxes                                        HTML     61K 
34: R19         Commitments and Contingencies                       HTML     31K 
35: R20         Subsequent Events                                   HTML     27K 
36: R21         Basis of Presentation, Summary of Significant       HTML    100K 
                Accounting Policies and Recent Accounting                        
                Pronouncements (Policies)                                        
37: R22         Basis of Presentation, Summary of Significant       HTML     42K 
                Accounting Policies and Recent Accounting                        
                Pronouncements (Tables)                                          
38: R23         Marketable Securities (Tables)                      HTML    100K 
39: R24         Fair Value Measurements (Tables)                    HTML     82K 
40: R25         Supplemental Financial Information (Tables)         HTML     46K 
41: R26         Leases (Tables)                                     HTML     62K 
42: R27         Debt (Tables)                                       HTML     41K 
43: R28         Stockholders? Equity (Tables)                       HTML     35K 
44: R29         Stock-Based Compensation (Tables)                   HTML     63K 
45: R30         Income Taxes (Tables)                               HTML     55K 
46: R31         Description of Organization and Business            HTML     54K 
                Operations (Details)                                             
47: R32         BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT       HTML     71K 
                ACCOUNTING POLICIES AND RECENT ACCOUNTING                        
                PRONOUNCEMENTS - Additional Information (Details)                
48: R33         BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT       HTML     34K 
                ACCOUNTING POLICIES AND RECENT ACCOUNTING                        
                PRONOUNCEMENTS - Schedule of Cash, Cash                          
                Equivalents and Restricted Cash (Details)                        
49: R34         BASIS OF PRESENTATION, SUMMARY OF SIGNIFICANT       HTML     38K 
                ACCOUNTING POLICIES AND RECENT ACCOUNTING                        
                PRONOUNCEMENTS - Schedule of Antidilutive                        
                Securities Excluded from Computation of Loss Per                 
                Share (Details)                                                  
50: R35         MARKETABLE SECURITIES - Summary of Marketable       HTML     65K 
                Securities (Details)                                             
51: R36         MARKETABLE SECURITIES - Summary of Unrealized Loss  HTML     55K 
                on Investments (Details)                                         
52: R37         MARKETABLE SECURITIES - Additional Information      HTML     36K 
                (Details)                                                        
53: R38         FAIR VALUE MEASUREMENTS - Summary of Fair Value,    HTML     73K 
                Assets and Liabilities Measured on Recurring Basis               
                (Details)                                                        
54: R39         FAIR VALUE MEASUREMENTS - Schedule of Level 3       HTML     33K 
                Liabilities Measured at Fair Value (Details)                     
55: R40         FAIR VALUE MEASUREMENTS - Schedule of Significant   HTML     40K 
                Unobservable Inputs (Details)                                    
56: R41         SUPPLEMENTAL FINANCIAL INFORMATION - Summary of     HTML     38K 
                Prepaid Expenses and Other Current Assets                        
                (Details)                                                        
57: R42         SUPPLEMENTAL FINANCIAL INFORMATION - Summary of     HTML     35K 
                Accrued Expenses and Other Current Liabilities                   
                (Details)                                                        
58: R43         LEASES - Additional Information (Details)           HTML     52K 
59: R44         LEASES - Summary of Lease, Cost (Details)           HTML     40K 
60: R45         LEASES - Summary of Supplemental Information        HTML     45K 
                Related To Lease (Details)                                       
61: R46         LEASES - Schedule of Finance Lease, Liability, to   HTML     32K 
                be Paid, Maturity (Details)                                      
62: R47         LEASES - Summary of Lessee, Operating Lease,        HTML     37K 
                Liability, Maturity (Details)                                    
63: R48         Debt - Additional Information (Details)             HTML     71K 
64: R49         Debt - Schedule of Outstanding Debt (Details)       HTML     41K 
65: R50         Debt - Schedule Of Interest Expense, Debt           HTML     44K 
                (Details)                                                        
66: R51         Debt - Schedule of Aggregate Principal Payments     HTML     42K 
                (Details)                                                        
67: R52         STOCKHOLDERS? EQUITY - Additional Information       HTML     67K 
                (Details)                                                        
68: R53         STOCKHOLDERS? EQUITY - Schedule of Weighted         HTML     35K 
                Assumptions For Estimated Fair Value of Warrant                  
                (Details)                                                        
69: R54         STOCK-BASED COMPENSATION - Additional Information   HTML     99K 
                (Details)                                                        
70: R55         STOCK-BASED COMPENSATION - Summary of Share-Based   HTML     32K 
                Compensation Expense Related to Stock Options                    
                (Details)                                                        
71: R56         STOCK-BASED COMPENSATION - Summary of Assumptions   HTML     46K 
                Used for Valuation of Fair Value of Stock                        
                (Details)                                                        
72: R57         STOCK-BASED COMPENSATION - Summary of Stock Option  HTML     68K 
                Activity (Details)                                               
73: R58         STOCK-BASED COMPENSATION - Summary of Restricted    HTML     39K 
                Stock Units Activity (Details)                                   
74: R59         INCOME TAXES - Additional Information (Details)     HTML     42K 
75: R60         INCOME TAXES - Summary of U.S. Statutory Federal    HTML     42K 
                Income Tax Rate to the Total Benefit for Income                  
                Taxes (Details)                                                  
76: R61         INCOME TAXES - Summary of Significant Components    HTML     56K 
                of the Company's Deferred Tax Assets (Details)                   
77: R62         Commitments and Contingencies (Details)             HTML     30K 
78: R63         Subsequent Events (Details)                         HTML     35K 
80: XML         IDEA XML File -- Filing Summary                      XML    147K 
83: XML         XBRL Instance -- abos-20231231_htm                   XML   1.29M 
79: EXCEL       IDEA Workbook of Financial Report Info              XLSX    138K 
12: EX-101.CAL  XBRL Calculations -- abos-20231231_cal               XML    239K 
13: EX-101.DEF  XBRL Definitions -- abos-20231231_def                XML    548K 
14: EX-101.LAB  XBRL Labels -- abos-20231231_lab                     XML   1.47M 
15: EX-101.PRE  XBRL Presentations -- abos-20231231_pre              XML    968K 
11: EX-101.SCH  XBRL Schema -- abos-20231231                         XSD    155K 
81: JSON        XBRL Instance as JSON Data -- MetaLinks              483±   737K 
82: ZIP         XBRL Zipped Folder -- 0001576885-24-000047-xbrl      Zip   3.71M 


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
Exhibit 97.1
ACUMEN PHARMACEUTICALS, INC.
POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION

1.Introduction

In accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Board of Directors (the “Board”) of Acumen Pharmaceuticals, Inc. (the “Company”) has adopted a policy (the “Policy”) providing for the Company’s recoupment of certain incentive-based compensation received by Covered Executives (as defined below) in the event that the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws.

2.Administration

Administration and enforcement of this Policy is delegated to the Compensation Committee of the Board (as constituted from time to time, and including any successor committee, the “Committee”). The Committee shall make all determinations under this Policy in its sole discretion. Determinations of the Committee under this Policy need not be uniform with respect to any or all Covered Executives and will be final and binding.

3.Effective Date

This Policy shall be effective as of October 2, 2023 (the “Effective Date”) and shall apply only to Covered Compensation (as defined below) that is received by Covered Executives on or after the Effective Date, except as otherwise agreed to by any Covered Executive.

4.Covered Executives

This Policy covers each current or former officer of the Company subject to Section 16 of the Securities Exchange Act of 1934, as amended (each, a “Covered Executive”).

5.Covered Compensation

This Policy applies to any cash-based and equity-based incentive compensation, bonuses, and awards that are received by a Covered Executive and that were based, wholly or in part, upon the attainment of any financial reporting measure (“Covered Compensation”). For the avoidance of doubt, none of the following shall be deemed to be Covered Compensation: base salary, a bonus that is paid solely at the discretion of the Committee or Board and not paid from a bonus pool determined by satisfying a financial reporting measure performance goal, and cash or equity-based awards that are earned solely upon satisfaction of one or more subjective or strategic standards. This Policy shall apply to any Covered Compensation received by an employee who served as a Covered Executive at any time during the performance period for that Covered Compensation.

6.Financial Restatements; Recoupment

In the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (such an accounting restatement, a “Restatement”), the Committee shall review the Covered Compensation received by a Covered Executive during the




three-year period preceding the Required Financial Restatement Date as well as any transition period that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years. Regardless of whether the Company filed the restated financial statements, the Committee shall, to the full extent permitted by governing law, seek recoupment of any Covered Compensation, whether in the form of cash or equity, received by a Covered Executive (computed without regard to any taxes paid), if and to the extent:

a.the amount of the Covered Compensation was calculated based upon the achievement of certain financial results that were subsequently the subject of a Restatement; and

b.the amount of the Covered Compensation that would have been received by the Covered Executive had the financial results been properly reported would have been lower than the amount actually awarded (any such amount, “Erroneously-Awarded Compensation”).

To the extent Covered Compensation was based on the achievement of a financial reporting measure, but the amount of such Covered Compensation was not awarded or paid on a formulaic basis, the Committee shall determine the amount, if any, of such Covered Compensation that is deemed to be Erroneously-Awarded Compensation.

For purposes of this Policy, the “Required Financial Restatement Date” is the earlier to occur of:

a.the date the Board, a committee of the Board, or any officer or officers authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or

b.the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.

For the avoidance of doubt, a Covered Executive will be deemed to have received Covered Compensation in the Company’s fiscal period during which the financial reporting measure specified in the award is attained, even if the Covered Executive remains subject to additional payment conditions with respect to such award.

7.Method of Recoupment

The Committee will determine, in its sole discretion, the method for recouping Erroneously-Awarded Compensation, which may include, without limitation:

a.requiring reimbursement of cash incentive compensation previously paid;

b.cancelling or rescinding some or all outstanding vested or unvested equity (and/or equity-based) awards;

c.adjusting or withholding from unpaid compensation or other set-off to the extent permitted by applicable law; and/or

d.reducing or eliminating future salary increases, cash-based or equity-based incentive compensation, bonuses, awards or severance.

8.Impracticability Exceptions







The Committee shall not seek recoupment of any Erroneously-Awarded Compensation to the extent it determines that:

a.the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of Erroneously-Awarded Compensation to be recovered;

b.recovery would violate home country law where that law was adopted prior to November 28, 2022; and/or

c.recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Sections 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.

9.No Indemnification

For the avoidance of doubt, the Company shall not indemnify any Covered Executive against the loss of any Erroneously-Awarded Compensation or any Covered Compensation that is recouped pursuant to the terms of this Policy, or any claims relating to the Company’s enforcement of its rights under this Policy.

10.Severability

If any provision of this Policy or the application of any such provision to any Covered Executive shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.

11.Amendments

The Committee may amend, modify or terminate this Policy in whole or in part at any time and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply with applicable laws and regulations.

12.No Impairment of Other Remedies

The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company may have, the Company’s ability to enforce, without duplication, the recoupment provisions set forth in any separate Company policy or in any Company plan, program or agreement (each, a “Separate Recoupment Policy” and collectively, the “Separate Recoupment Policies”), or any actions that may be imposed by law enforcement agencies, regulators or other authorities. Notwithstanding the foregoing, in the event that there is a conflict between the application of this Policy to a Covered Executive in the event of a Restatement and any additional recoupment provisions set forth in a Separate Recoupment Policy to which a Covered Executive is subject, the provisions of this Policy shall control. The Company may also adopt additional Separate Recoupment Policies in the future or amend existing requirements as required by law or regulation.




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/26/248-K
For Period end:12/31/23
10/2/23
11/28/22
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/27/24  Acumen Pharmaceuticals, Inc.      S-3                    8:1.2M                                   Workiva Inc Wde… FA01/FA


7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/08/23  Acumen Pharmaceuticals, Inc.      8-K:5,9     6/06/23   11:1.8M
 5/09/23  Acumen Pharmaceuticals, Inc.      10-Q        3/31/23   51:9.1M
 3/27/23  Acumen Pharmaceuticals, Inc.      10-K       12/31/22   73:25M
 3/15/23  Acumen Pharmaceuticals, Inc.      8-K:5,9     3/09/23   11:391K
 3/28/22  Acumen Pharmaceuticals, Inc.      10-K       12/31/21   73:12M                                    Donnelley … Solutions/FA
 6/24/21  Acumen Pharmaceuticals, Inc.      S-1/A                 13:5.4M                                   Donnelley … Solutions/FA
 6/09/21  Acumen Pharmaceuticals, Inc.      S-1                   10:5.2M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001576885-24-000047   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 10:24:20.1am ET